Théa is excited to inform that their partner OliX Pharmaceuticals, Inc. a leading developer of RNAi therapeutics, announced on march 27th that the first patient has been successfully dosed in the phase 1 clinical trial evaluating OLX10212, an investigational RNAi therapeutic intended for the treatment of age-related macular degeneration (AMD), including geographic atrophy (GA) and neovascular (nv) AMD.
OLX10212 targets inflammation pathways that play a key role in the development of GA and nvAMD. OliX Pharmaceuticals will evaluate the safety and tolerability of OLX10212 administered by intravitreal injection in up to 60 patients with nvAMD in a Phase 1 clinical trial in a multi-center, single- and multi-dose, dose-escalation study in the US.
Théa is thrilled to support this development according to the licensing agreement onset in 2019 and which has been expanded through Théa Open Innovation. OliX granted Théa worldwide rights excluding Asia-Pacific.
